The spine device industry spent the first half of 2026 selling surgeons on smaller, smarter and more autonomous tools. It spent that same six months fielding a harder question from the hospitals buying them: does any of it actually pay off?
Medtronic supplied both sides of that story. The company’s Stealth AXiS spine system earned FDA clearance in February, and by April surgeons were debuting its “autopilot” navigation features in live cases — part of a broader push in which Medtronic has positioned itself as a “force multiplier” for surgeons managing rising case volumes, backed by data showing the company dominates lumbar and cervical device usage nationally. But the same company also spent January defending against a lawsuit alleging its spinal fusion implants fractured after surgery, and in April disclosed a network breach that exposed data. In May, the company agreed to acquire a pain management company for $650 million.
As a handful of large manufacturers absorb more of the navigation, robotics and implant market, a hospital’s purchasing decision increasingly comes bundled with exposure to that vendor’s legal, operational and cybersecurity risk, not just its clinical performance.
The robotics honeymoon is over
If 2023 and 2024 were the years hospitals announced which robotics platform they’d bought, 2026 is shaping up as the year they start asking whether it worked.
Spine leaders spent much of the spring publicly reckoning with that question. Some hospitals never see a return on their spine robotics investment, pointing to underused platforms, thin case volumes and steep training curves that erode the promised efficiency gains. Experienced surgeons also wonder about the , arguing that surgeons trained primarily on robotic assistance may be losing the manual dexterity needed when a case doesn’t go as planned and a workforce risk that doesn’t necessarily show up on the immediate term pros and cons of the robotics program.
There are many hospitals and ASCs feeling the pressure to acquire robots as a recruiting tool for early career surgeons and that could backfire amid cyberattacks and network disruptions. It’s also a challenge for ASCs and smaller hospitals as the financial model changes and there is more focus on value-based care. Insurance companies don’t pay more for the robot’s appearance, but the subscription use and disposables add to the global cost for the procedures.
An American Spine Registry analysis found robotic and computer-assisted use has plateaued in spine surgery rather than continuing the steep adoption curve manufacturers have banked on. The market is moving past the early-adopter phase and into a harder, slower-growing phase where every additional robotics sale requires health systems to show, not just assume, a return.
The next device might fit in a pocket
Even as robotics adoption cools, a different kind of technology story is picking up: miniaturization. One of the year’s most closely followed pieces described spine surgery’s next frontier as something that may fit in a surgeon’s hand — smaller, more portable navigation and imaging tools built to work around, rather than replace, existing operating room workflows.
That shift toward smaller and more integrated hardware is also showing up as a crossover with consumer technology. In San Diego, a surgeon combined Stryker and Apple technologies to perform the region’s first spinal fusion built around that pairing, an early sign that consumer hardware and software, not just traditional medtech R&D pipelines, are starting to shape how spine navigation gets built.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
